Live signal feed

The chain others read separately, joined in time.

NIH grant → clinical trial → public-company event. We snapshot all three daily and surface the upstream move before the downstream one is news. Last snapshot 2026-09-19 · 46 signals · 80 grants, 153 trials, 10438 tickers indexed.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingNVS55% conf

NOVARTIS AG (NVS) — PHASE3 primary completion in ~160 days

Upstream (observed)
Clinical trial status (PHASE3) — Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN55% conf

AMGEN INC (AMGN) — PHASE3 primary completion in ~124 days

Upstream (observed)
Clinical trial status (PHASE3) — Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~60 days

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVS55% conf

NOVARTIS AG (NVS) — PHASE1 primary completion 51 days ago (readout window)

Upstream (observed)
Clinical trial status (PHASE1) — Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingMDCE35% conf

Medical Care Technologies Inc. (MDCE) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingARGX35% conf

ARGENX SE (ARGX) — trial protocol updated 1 days ago

Upstream (observed)
Clinical trial status (n/a) — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE1 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingARWR35% conf

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE2 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE3 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Area heat50% conf

"obesity" heating up — 0 grants ($0), 34 active trials (16 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat50% conf

"Alzheimer" heating up — 11 grants ($323,634,614), 34 active trials (11 started <12 mo)

Upstream (observed)
NIH grant velocity — 11 grants, $323,634,614 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Grant → Trial42% conf

NIH-funded research entered the clinic: "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma"

Upstream (observed)
NIH RePORTER grant — NATIONAL CANCER INSTITUTE — Biomedical Information Technology, Software Development, and Informatics Support (FY2025, $30,861,067) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Releva…"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recur…"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Transcranial Random Noise (tRNS) for BPSD in Alzheimer's Disease: A Double-blind Randomiz…"

Upstream (observed)
NIH RePORTER grant — VANDERBILT UNIVERSITY MEDICAL CENTER — All of Us Research Program Data and Research Center (FY2025, $40,678,454) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Personalized Brain Health Service and Dementia Prevention"

Upstream (observed)
NIH RePORTER grant — COG RESEARCH FOUNDATION, LLC — COG NCTN Network Group Operations Center (FY2026, $19,388,538) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance"

Upstream (observed)
NIH RePORTER grant — OHIO STATE UNIVERSITY — Analyses to Reveal Trajectories and Early Markers of Imminent Shifts in Suicida… (FY2025, $19,515,757) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
label expansion / commercial milestone (6-18 mo, base rate 60%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Qual…"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Georgia CEAL RESTORES Family Diabetes Study"

Upstream (observed)
NIH RePORTER grant — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — Consortium for Advancing Management and Prevention of Cancer in People with HIV (FY2026, $21,522,826) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes"

Upstream (observed)
NIH RePORTER grant — RESEARCH TRIANGLE INSTITUTE — Defining Evidence for Programs to Ensure Nutrition for Development (DEPEND) Coo… (FY2026, $32,500,000) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Cooking Health-Oriented Meals to Prevent Dementia and Diabetes"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Area heat23% conf

"GLP-1" heating up — 0 grants ($0), 2 active trials (1 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Grant → Trial21% conf

NIH-funded research entered the clinic: "Mulligan Mobilization With Movement Versus Conventional Physiotherapy on Ankle Range of M…"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — Comparative Medicine Infectious Diseases- Bethesda (FY2025, $49,577,192) · joined via shared research target "experimental"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Area heat20% conf

"immunotherapy" heating up — 0 grants ($0), 2 active trials (0 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)